Dev

Eli Lilly has been granted approval in the EU for Amyvid, a solution to diagnose Alzheimer’s disease. Amyvid (florbetapir [18F]) is used as an imaging agent during positron emission tomography (PET) scanning to detect the presence or absence of beta-amyloid…

Global Burden of Disease Study 2010 published in The Lancet Deaths due to Alzheimer’s disease and related dementias have jumped more than threefold worldwide since 1990, according to the Global Burden of Disease Study 2010. Published in December 2012 in…

Brain research in Europe needs a decisive and concerted effort with more investment and clearer and more innovative research and healthcare strategies. The European Commission decided in 2012 to make May 2013 the European Month of the Brain with the…

A recent study suggests that the combined risk factors for heart disease and stroke (including high blood pressure, high cholesterol, smoking and obesity) may also increase the risk of cognitive decline. For their analysis, the researchers used data from an…

Data extracted from existing publicly- and privately-conducted clinical trials to address amyotrophic lateral sclerosis (ALS) The largest collection of data from clinical trials in amyotrophic lateral sclerosis (ALS), representing more than 8,500 individuals, is now live. The Pooled Resource Open-Access…

The Innovative Medicines Initiative (IMI) has launched its latest call for proposals, including a topic on neurodegenerative disorders entitled “Developing an aetiology-based taxonomy of human disease.” The topic aims to develop a new classification for neurodegenerative disorders, with a focus…

International B.R.A.I.N. Prize awarded to disruptive innovations in brain technology The Breakthrough Research And Innovation in Neurotechnology (B.R.A.I.N.) Prize is an international award granted in Israel to an individual, group or organization for a recent, practical breakthrough in the field…